473 0 Kommentare Novavax to Host Conference Call to Discuss First Quarter 2017 Financial Results on May 8, 2017

GAITHERSBURG, Md., May 01, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2017 financial and operating results following the close of U.S. financial markets on Monday, May 8, 2017.

Conference call details are as follows:

Date:			Monday, May 8, 2017
Time:			4:30 p.m. U.S. Eastern Time (ET)
Dial-in number:			(877) 212-6076 (Domestic) or (707) 287-9331 (International)
Passcode:			15607801
Webcast:			www.novavax.com, "Investors"/ "Events"

Conference call and webcast replay:

Dates:			Starting at 7:30 p.m. ET, May 8, 2017, until 7:30 p.m. ET, May 15, 2017
Dial-in number:			(855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode:			15607801
Webcast:			www.novavax.com, "Investors"/ "Events"

About Novavax

Lesen Sie auch

Kein Ausblick

Evotec crasht nach Zahlen um ein Drittel auf Tiefststand seit 2017

heute 11:36

Gewinn, Umsatz über Erwartung

Novartis hebt Prognosen an: Starke Medikamentenverkäufe treiben Wachstum

gestern 08:18

Verlierer des Tages

Sartorius-Aktie tiefrot: "Weiteres Abwärtspotenzial"

18.04.24, 12:00

Earnings Preview

Das sind die Top 10 der diese Woche wichtigsten US-Quartalszahlen – Teil 2

heute 18:23

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Contact:

Investor Relations
Novavax, Inc.
Andrea N. Flynn, Ph.D.
Associate Director, Investor Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
david.schull@russopartnersllc.com 
212-845-4271

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire